1. Home
  2. DAIO vs TPST Comparison

DAIO vs TPST Comparison

Compare DAIO & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Data I/O Corporation

DAIO

Data I/O Corporation

HOLD

Current Price

$3.60

Market Cap

22.3M

Sector

Industrials

ML Signal

HOLD

Logo Tempest Therapeutics Inc.

TPST

Tempest Therapeutics Inc.

HOLD

Current Price

$1.27

Market Cap

26.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DAIO
TPST
Founded
1969
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.3M
26.2M
IPO Year
1995
2012

Fundamental Metrics

Financial Performance
Metric
DAIO
TPST
Price
$3.60
$1.27
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$5.22
$11.00
AVG Volume (30 Days)
138.5K
115.7K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$21,500,000.00
$295,000.00
Revenue This Year
$4.51
N/A
Revenue Next Year
$30.29
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.16
$1.23
52 Week High
$4.49
$12.22

Technical Indicators

Market Signals
Indicator
DAIO
TPST
Relative Strength Index (RSI) 55.27 29.29
Support Level $2.98 N/A
Resistance Level $4.49 $2.48
Average True Range (ATR) 0.32 0.10
MACD -0.00 -0.05
Stochastic Oscillator 39.32 4.20

Price Performance

Historical Comparison
DAIO
TPST

About DAIO Data I/O Corporation

Data I/O Corp is a provider of programming, security deployment, security provisioning, and associated Intellectual Property protection and management solutions used in electronics manufacturing with flash memory, microcontrollers, and flash memory-based intelligent devices as well as secure element devices, authentication devices, and secure microcontrollers. It is engaged in focused on the design, manufacturing and sale of programming systems used by designers and manufacturers of electronic products. It has its geographic presence in the United States, Europe, and Asia and others. The company derives the majority of its revenue from Asia and others.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Share on Social Networks: